Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye

EMBO Molecular Medicine

Volumn 6, Issue 5, 2014, Pages 604-623

  Michael, Iacovos P ^a   Westenskow, Peter D ^b   Hacibekiroglu, Sabiha ^a,c   Greenwald, Alissa Cohen ^a   Ballios, Brian G ^c   Kurihara, Toshihide ^b   Li, Zhijie ^c   Warren, Carmen M ^d   Zhang, Puzheng ^a   Aguilar, Edith ^b   Donaldson, Laura ^c   Marchetti, Valentina ^b   Baba, Takeshi ^a   Hussein, Samer M ^a   Sung, Hoon Ki ^a   Iruela Arispe, M Luisa ^d   Rini, James M ^c   Van der Kooy, Derek ^c   Friedlander, Martin ^b   Nagy, Andras ^a,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Diabetic retinopathy; Retinopathy of prematurity; Sticky trap; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; STICKY TRAP; UNCLASSIFIED DRUG; VASCULOTROPIN; BIOLOGICAL PRODUCT; HYBRID PROTEIN; RECOMBINANT PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHOROID CAPILLARY LAYER; CILIARY BODY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG HALF LIFE; DRUG SAFETY; EXTRACELLULAR MATRIX; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; TRACHEAL BLOOD VESSEL; WOUND HEALING; DRUG EFFECTS; EYE; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC;

BIOLOGICAL PRODUCTS; EYE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899868974     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201303708     Document Type: Article

References (74)

1. Abrishami M, Zarei-Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B (2009) Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina 29: 699-703
2. Agha-Mohammadi S, O'Malley M, Etemad A, Wang Z, Xiao X, Lotze MT (2004) Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med 6: 817-828
3. Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. N Engl J Med 366: 1227-1239
4. Avery RL (2012) Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS 16: 2-4
5. Ballios BG, Cooke MJ, van der Kooy D, Shoichet MS (2010) A hydrogel-based stem cell delivery system to treat retinal degenerative diseases. Biomaterials 31: 2555-2564
6. Banin E, Dorrell MI, Aguilar E, Ritter MR, Aderman CM, Smith AC, Friedlander J, Friedlander M (2006) T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci 47: 2125-2134
7. Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM, Weinerman A, Emmenegger U, Ma L, Thorpe P et al (2004) Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 64: 6616-6625
8. Boehm S, Rothermundt C, Hess D, Joerger M (2010) Antiangiogenic drugs in oncology: a focus on drug safety and the elderly-a mini-review. Gerontology 56: 303-309
9. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM (2010) Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet oncology 11: 373-382
10. Bui BV, Fortune B (2004) Ganglion cell contributions to the rat full-field electroretinogram. J Physiol 555: 153-173
11. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9: 653-660
12. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936
13. Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6: 465-477
14. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884-896
15. Cortes J, Caralt M, Delaloge S, Cortes-Funes H, Pierga JY, Pritchard KI, Bollag DT, Miles DW (2012) Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer 48: 475-481
16. Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE (2013) Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 98: F170-F174
17. Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T (2005) Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122: 473-483
18. Dong CJ, Hare WA (2000) Contribution to the kinetics and amplitude of the electroretinogram b-wave by third-order retinal neurons in the rabbit retina. Vision Res 40: 579-589
19. Dorrell MI, Aguilar E, Friedlander M (2002) Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. Invest Ophthalmol Vis Sci 43: 3500-3510
20. Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J, Banin E, Ramirez GA, Gasmi M, Bird A et al (2009) Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest 119: 611-623
21. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104: 17069-17074
22. Ellis LM (2005) Bevacizumab. Nat Rev Drug Discov Suppl: S8-S9
23. Eremina V, Cui S, Gerber H, Ferrara N, Haigh J, Nagy A, Ema M, Rossant J, Jothy S, Miner JH et al (2006) Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 17: 724-735
24. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716
25. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400
26. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974
27. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286
28. Gasparini G, Longo R, Toi M, Ferrara N (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2: 562-577
29. Ghetie V, Ward ES (1997) FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18: 592-598
30. Glaser SM, Hughes IE, Hopp JR, Hathaway K, Perret D, Reff ME (2005) Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies. J Biol Chem 280: 41494-41503
31. Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6: 507-518
32. Hanneken A, de Juan E Jr, Lutty GA, Fox GM, Schiffer S, Hjelmeland LM (1991) Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol 109: 1005-1011
33. Hard AL, Hellstrom A (2011) On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment-a review. Acta Paediatr 100: 1523-1527
34. Heath VL, Bicknell R (2009) Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6: 395-404
35. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398
36. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267: 26031-26037
37. Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358: 2606-2617
38. Janoria KG, Gunda S, Boddu SH, Mitra AK (2007) Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 4: 371-388
39. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC et al (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560-H576
40. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049
41. Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, Kim M, Kim KE, Kim H, Lim NK et al (2010) Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18: 171-184
42. Krilleke D, DeErkenez A, Schubert W, Giri I, Robinson GS, Ng YS, Shima DT (2007) Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. J Biol Chem 282: 28045-28056
43. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M (2012) Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 122: 4213-4217
44. Ladomery MR, Harper SJ, Bates DO (2007) Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett 249: 133-142
45. Li Z, Michael IP, Zhou D, Nagy A, Rini JM (2013) Simple piggyBac transposon-based mammalian cell expression system for inducible protein production. Proc Natl Acad Sci USA 110: 5004-5009
46. Matsunaga N, Ozeki H, Hirabayashi Y, Shimada S, Ogura Y (2005) Histopathologic evaluation of the internal limiting membrane surgically excised from eyes with diabetic maculopathy. Retina 25: 311-316
47. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658
48. Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364: 603-615
49. Mueller BM, Reisfeld RA, Gillies SD (1990) Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA 87: 5702-5705
50. Munoz EM, Linhardt RJ (2004) Heparin-binding domains in vascular biology. Arterioscler Thromb Vac Biol 24: 1549-1557
51. Nazer B, Humphreys BD, Moslehi J (2011) Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 124: 1687-1691
52. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8: 1369-1375
53. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP et al (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171: 53-67
54. Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M (2002) Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med 8: 1004-1010
55. Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL (2011) Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther 27: 219-224
56. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15: 171-185
57. Park JE, Keller GA, Ferrara N (1993) The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4: 1317-1326
58. Parker MW, Xu P, Li X, Vander Kooi CW (2012) Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem 287: 11082-11089
59. Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, Wadsworth SC, Scaria A (2009) Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 16: 10-16
60. Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C (2010) Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol (Copenh) 88: e136
61. Robinson CJ, Stringer SE (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114: 853-865
62. Scheppke L, Aguilar E, Gariano RF, Jacobson R, Hood J, Doukas J, Cao J, Noronha G, Yee S, Weis S et al (2008) Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest 118: 2337-2346
63. Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y (2009) An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. J Immunol 182: 5537-5546
64. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101-111
65. Stewart MW (2012) The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 87: 77-88
66. Stewart MW, Grippon S, Kirkpatrick P (2012a) Aflibercept. Nat Rev Drug Discov 11: 269-270
67. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF (2012b) Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 32: 434-457
68. Sun K, Wernstedt Asterholm I, Kusminski CM, Bueno AC, Wang ZV, Pollard JW, Brekken RA, Scherer PE (2012) Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci USA 109: 5874-5879
69. Thebaud B (2007) Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. Neonatology 91: 291-297
70. Tissot van Patot MC, Leadbetter G, Keyes LE, Bendrick-Peart J, Beckey VE, Christians U, Hackett P (2005) Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol 98: 1626-1629
71. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W (2000) Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 97: 7963-7968
72. Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7: 475-485
73. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844
74. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hamalainen R, Cowling R, Wang W, Liu P, Gertsenstein M et al (2009) piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458: 766-770